logo
  

Biogen Submits Final Protocol For Envision Trial Of Aduhelm On Alzheimer's Disease

Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug Administration for review and approval.

The company expects the first patient to enter screening in May 2022 and the trial's primary completion approximately four years after the study begins.

The confirmatory trial is a requirement based on FDA's accelerated approval of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease.

The study will be a global, placebo-controlled trial, aiming to enroll around 1,500 patients with early Alzheimer's disease and confirmation of amyloid beta pathology.

The company has also reaffirmed the trial's goal of recruiting at least 18 percent of patients in the U.S. from Black/African American and Latino communities.

Aduhelm is indicated for the treatment of Alzheimer's disease. Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Aduhelm is a monoclonal antibody directed against amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 6 percent in the morning trading in Germany after the package delivery and logistic major reported Friday higher profit and revenues in its second quarter with strong demand. Going ahead, the company confirmed its 2022 EBIT guidance of 8.0 billion euros, plus or minus 5 percent, even in consideration of a possible global economic downturn. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday net income for the first quarter halved from last year, hurt by a 1 decline in revenues and a decrease in the market prices of its equity investments in publicly-traded companies. Shares of Deutsche Lufthansa AG were gaining around 6 percent in the morning trading after the German flag carrier reported Thursday a profit in its second quarter, compared to last year's loss, benefited by surge in demand. The company also specified its outlook for the year, and now expects adjusted EBIT to be above 500 million euros for the full year of 2022, in line with current market.
Follow RTT